Duvelisib (IPI-145)

Catalog No.S7028 Synonyms: INK1197

For research use only.

Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.

Duvelisib (IPI-145) Chemical Structure

CAS No. 1201438-56-3

Selleck's Duvelisib (IPI-145) has been cited by 38 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.
Targets
PI3Kδ [1]
(Cell-free assay)
PI3Kβ [1]
(Cell-free assay)
PI3Kγ [1]
(Cell-free assay)
23 pM(Ki) 1564 pM(Ki) 243 pM(Ki)
In vitro

IPI-145 suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat M3LZcHBzd2yrZnXyZZRqd25iYYPzZZk> MWezJIRigXN? MnrJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCMdYLrZZQh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGlEPTB;MT65JO6ddQ>? M3WzO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6=
MOLT4 NUTkblhMWHKxbHnm[ZJifGmxbjDhd5NigQ>? M4DQ[VMh\GG7cx?= MWnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTGS0JINmdGy|IHHmeIVzKDNiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxRTJwMzFOwG0> NUHJdVZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=>
MV4-11 NFv2UnJRem:uaX\ldoF1cW:wIHHzd4F6 M3LFTFMh\GG7cx?= NGfiUFNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3ME20MlQh|ryP NIn1TYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+
MOLM14 MkDKVJJwdGmoZYLheIlwdiCjc4PhfS=> Mk\WN{Bl[Xm| NFLsOHFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3ME2xMlIh|ryP MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd5NEGyO{c,Ojd5N{SxNlc9N2F-
Loucy NITrVVlRem:uaX\ldoF1cW:wIHHzd4F6 M{HC[VMh\GG7cx?= MkjPRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCOb4XjfUBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OD1yLkm4JO69VQ>? MmX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?=
JURKAT MojFSpVv[3Srb36gZZN{[Xl? NWrhc|VFOC5zLDCxMlAtKGGwZDC5MlAh|ryP NGSzPHlKWElzNEWge4F{KGGkbHWgeI8hcW6qaXLpeEBCc3RiYX7kJHM3KHCqb4PwbI9zgWyjdHnvckBidmRibX;k[ZN1dHliYX\m[YN1\WRiZ4Lve5RpKGmwIFrVVmtCXA>? M4CyT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUewNlY{Lz5|MEm3NFI3OzxxYU6=
MOLT3 NXGybZR1TnWwY4Tpc44h[XO|YYm= NHnmO2YxNjFuIEGuNEwh[W6mIEmuNEDPxE1? MnHWTXBKOTR3IIfhd{Bi[mynIITvJIlvcGmkaYSgRYt1KGGwZDDTOkBxcG:|cHjvdplt[XSrb36gZpV1KGKjcnXsfUBi\m[nY4Tl[EB1cGViZ4Lve5RpKG:oIF3PUHQ{KFRvQVzM Mk[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB7N{CyOlMoRjNyOUewNlY{RC:jPh?=
Raji32 MX7GeY5kfGmxbjDhd5NigQ>? Moe4NUDPxE1? NFnrcFZm\m[nY4TpeoVtgSCrbYDhbZJm\CC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFsfA>? NITwfJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW4OFI2PCd-M{C1PFQzPTR:L3G+
Ramos460 NILjZ4VHfW6ldHnvckBie3OjeR?= NFP4O44yKM7:TR?= MXTl[oZm[3SrdnXsfUBqdXCjaYLl[EB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> M4\VclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNUi0NlU1Lz5|MEW4OFI2PDxxYU6=
HBL-1 NWHBWJRPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmLuS2k2OD13LkOg{txO NVPzb5hURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
OCI-Ly3 MnLiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUTHTVUxRTNwNzFOwG0> NEfDb4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
TMD-8 MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\WbI5IUTVyPUCuNFAxPSEQvF2= MkexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
U-2932 NHO1fHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkLiS2k2OD1zLkig{txO MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB4N{e3NUc,OzByNke3O|E9N2F-
Farage NYHROo96T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mny3S2k2OD1yLkC0JO69VQ>? NUPDeYI6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
SU-DHL-10 MoPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIraVmpIUTVyPUKuOEDPxE1? NUDaVVhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
SU-DHL-4 M3rOZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIDDNJZIUTVyPUCuNkDPxE1? NVn4ZpZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
Karpas-422 MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYL3WHFIT0l3ME2wMlEh|ryP M3e0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
DOHH-2 NYTvb4tuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUL5TndoT0l3ME2wMlA2KM7:TR?= NHHyZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC2O|c4OSd-M{CwOlc4PzF:L3G+
WSU-NHL NEPycplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MW\HTVUxRTBwMEC4JO69VQ>? M1\WdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
Jeko-1 MmPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV[0RlBbT0l3ME2xMlMh|ryP MoTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNke3O|EoRjNyME[3O|cyRC:jPh?=
Mino MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2PLc2dKPTB;Mz60JO69VQ>? NXvDVXFWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
NCI-H929 NETiNINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYq5cY5kT0l3ME2xJO69VQ>? NVvzfJFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOlc4PzFpPkOwNFY4PzdzPD;hQi=>
HH MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPGS2ZET0l3ME2wMlAyKM7:TR?= M{O5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyME[3O|cyLz5|MEC2O|c4OTxxYU6=
BJAB NYfuXI1US2WubDD2bYFjcWyrdImgZZN{[Xl? NHTrfXYxNjFuIEGsJFUh|ryP NGnmcYE1QCCjbnSgO|IhcA>? M1f4eIlvcGmkaYTl[EBk\WyuIHfyc5d1cA>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{MkK3PEc,Ojl3MkKyO|g9N2F-
LCL NV;aRXUzS2WubDD2bYFjcWyrdImgZZN{[Xl? Ml\aNE4yNCBzLDC1JO69VQ>? NFexUGI1QCCjbnSgO|IhcA>? NX;jb2RicW6qaXLpeIVlKGOnbHyg[5Jwf3Sq NFn2XoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyNlI4QCd-Mkm1NlIzPzh:L3G+
insect cells NYLWWpMyTnWwY4Tpc44h[XO|YYm= NFHQeHE2KG2rboO= NGGyOoRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIFOteIVzdWmwYXygTIl{Pi22YXfn[YQheDFzMHfhcY1iKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMhfXOrbnegdIhwe3CqYYTp[JltcW6xc3n0c4wh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKGejbX3hMVMzWC2DVGCgZYZ1\XJiNTDtbY5{KGK7IITobY4hdGG7ZYKgZ4hzd22jdH;ndoFxcGmlIH3leIhw\CxiSVO1NEA:KDBwMTFOwG0v NIfxNXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{ODN7NUCyM{c,S2iHTVLMQE9iRg>?
Sf21 NEPWZ2FHfW6ldHnvckBie3OjeR?= M3Pye|UhdWmwcx?= MoexTY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKHBzMUDk[Yx1[S:3boTh[4dm\CC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSClZXzsd{B2e2mwZzDwbI9{eGijdHnkfYxqdm:|aYTvcEBieyC|dXLzeJJifGViaX6gdJJme2WwY3Wgc4Yh\2GvbXGtN|JRNUGWUDDh[pRmeiB3IH3pcpMh[nlidHjpckBtNCCLQ{WwJF0hOC5zIN88UU4> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNFM6PTB{Lze+R4hGVUKOPD;hQi=>
splenic B MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NFLQeFg{OCCvaX7z NE\yR2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJidGJxYzDtc5V{\SC|cHzlcolkKEJiY3XscJMheHKnaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KEySUzDvdkBHMGGkJzmyJIRwdmuneTDhcpRqNW2xdYPlJGloVSCjbnSgdoVkd22kaX7hcpQhdW:3c3WgTWw1KHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIhSmy3ZTDy[YR2[3Srb36gZZN{[XluIFXDOVAhRSByLkGg{txONg>? NGn0S4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{ODN7NUCyM{c,S2iHTVLMQE9iRg>?
Sf21 NHrD[ndHfW6ldHnvckBie3OjeR?= NFG0OZY2KG2rboO= NGjXRnZKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5icEGxNIJmfGFxdX70ZYdo\WRicnXjc41jcW6jboSg[pVtdCCuZX7neIgheDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiY3XscJMhfXOrbnegdIhwe3CqYYTp[JltcW6xc3n0c4wh[XNic4Xid5Rz[XSnIHnuJJBz\XOnbnPlJI9nKGejbX3hMVMzWC2DVGCgZYZ1\XJiNTDtbY5{KGK7IITobY4hdGFuIFnDOVAhRSBzIN88UU4> MoDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|A{QTVyMj:nQmNpTU2ETEyvZV4>
Sf21 M3:wTWZ2dmO2aX;uJIF{e2G7 NYjqc2VTPSCvaX7z MY\Jcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4heDFzMHHsdIhiN3WwdHHn[4VlKHKnY3;tZolv[W62IH\1cIwhdGWwZ4ToJIh2dWGwIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJINmdGy|IIXzbY5oKHCqb4PwbIF1cWS7bHnuc5NqfG:uIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDnZY1u[S1|MmCtRXRRKGGodHXyJFUhdWmwczDifUAtKEmFNUCgQUAyOCEQvF2u MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|A{QTVyMj:nQmNpTU2ETEyvZV4>
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-MAPK / MAPK ; PI3Kγ / PI3Kδ 27174919 29522278
In vivo IPI-145 (10 mg/kg, p.o.) shows well pharmacokinetics with Cmax and AUC of 390 ng/mL and 137 ng•h/mL in mouse and rat. IPI-145 (10 mg/kg) is active in murine DTH model with ~50% ear swelling. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model. IPI-145 prevents inflammation and protects joint bone and cartilage in the rat CIA model. IPI-145 (10 mg/kg,QD) demonstrates activity in rat adjuvant induced polyarthritis model. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 416.86
Formula

C22H17ClN6O

CAS No. 1201438-56-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C1=CC2=C(C(=CC=C2)Cl)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02307461 Completed Drug: IPI-145 (duvelisib)|Drug: IPI-145 Healthy SecuraBio November 2014 Phase 1
NCT02095587 Completed Drug: IPI-145 Hepatic Impairment SecuraBio March 2014 Phase 1
NCT01947777 Completed Drug: IPI-145|Drug: Rifampin Healthy SecuraBio October 2013 Phase 1
NCT01925911 Completed Drug: IPI-145|Drug: Midazolam Healthy SecuraBio August 2013 Phase 1
NCT01836861 Completed Drug: IPI-145 Healthy SecuraBio March 2013 Phase 1
NCT01549106 Completed Drug: IPI-145|Drug: Placebo Healthy Volunteers SecuraBio August 2011 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Whether IPI-145 S7028 is mixture of two chiral forms, if not, which form is it?

Answer:
S7028 IPI-145 is S form.

Tags: buy Duvelisib|Duvelisib ic50|Duvelisib price|Duvelisib cost|Duvelisib solubility dmso|Duvelisib purchase|Duvelisib manufacturer|Duvelisib research buy|Duvelisib order|Duvelisib mouse|Duvelisib chemical structure|Duvelisib mw|Duvelisib molecular weight|Duvelisib datasheet|Duvelisib supplier|Duvelisib in vitro|Duvelisib cell line|Duvelisib concentration|Duvelisib nmr|Duvelisib in vivo|Duvelisib clinical trial|Duvelisib inhibitor|Duvelisib Angiogenesis inhibitor